Caris Life Sciences, Genentech Announce Oncology Collaboration Worth $1.1 Billion

By Bio-IT World Staff 

December 17, 2025 | Caris Life Sciences yesterday announced that its therapeutic research arm, Caris Discovery, has entered into a multi-year collaboration and license agreement with Genentech, a member of the Roche Group.  

“Caris Discovery’s approach to identifying novel drug targets leverages our biobank of more than 500,000 patients tissue samples, matched with comprehensive molecular data and clinical outcomes,” Milan Radovich, PhD, Senior Vice President and Chief Scientific Officer at Caris told Bio-IT World. “We also utilize our proprietary proteomics technologies that allow us to identify high cancer-specific proteins from patient tissues. We can tailor target discovery campaigns to almost any cancer population imaginable. This includes tumors that have developed resistance to standard-of-care therapies, where new therapeutic approaches are urgently needed.”  

In this collaboration, Caris will work to identify and validate novel oncology targets in solid tumor tissue. 

Under the terms of the agreement, Caris is eligible to receive upfront and near-term payments of $25 million and is also eligible for up to $1.1 billion of potential research, development, commercial, and net sales milestone payments, as well as potential tiered royalties on net sales of collaboration therapies. 

Caris Discovery scientists use an integrated bioinformatics and wet-lab workflow, which combines interrogation of solid tissue and cell-based systems with multimodal data to validate prioritized targets and help advance the development of next generation therapies. 

“Both Caris and Genentech are pioneers in precision medicine with clinical genomics and therapeutic development, respectively, with a shared commitment to improve the lives of patients affected by cancer,” Radovich continued. “This partnership sets the stage to help identify novel targets for the next generation of precision medicines against this disease.” 

“Roche and Genentech are driven by a profound vision— future where cancer can be cured," said Boris L. Zaïtra, Head of Roche Corporate Business Development, in a statement. “We have successfully led many fundamental scientific advances in oncology. As we continue to bring forth transformative medicines, collaborations with partners such as Caris allow us to pursue future innovation for patients with unmet needs.”